The Daily Buyout
UndisclosedStrategic acquisitionHealthcare & Life Sciences

Lilly to Acquire Autoimmune Biotech Merida Biosciences

Eli Lilly signed a definitive agreement to acquire Merida Biosciences, developer of antibody-degrading biologics for autoimmune and allergic diseases, with lead candidate MER511 in Phase 1.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

More Healthcare & Life Sciences deals